Thus, this is the first study showing the in vitro and in vivo growth inhibitory properties of Bortezomib in a salivary gland carcinoma cell line (SALTO-5) and the in vivo effects of Bortezomib on tumor-infiltrating immune cells, tumor vessels density, expression of ErbB2, AKT and cleaved caspase 3 and molecules involved in proteasome structural composition in SALTO-5 cell line transplanted in BALB-neuT mice. Here, ERBB2 is linked to salivary gland carcinoma.